4.0 Article

Circulating Levels of Calcitonin Gene-Related Peptide Are Lower in COVID-19 Patients

Journal

JOURNAL OF THE ENDOCRINE SOCIETY
Volume 5, Issue 3, Pages -

Publisher

ENDOCRINE SOC
DOI: 10.1210/jendso/bvaa199

Keywords

COVID-19; CGRP; RAMP1; proton pump inhibitors; type II pneumocyte hyperplasia; airway hyperresponsiveness; ILC2

Funding

  1. Fundacion Rioja Salud

Ask authors/readers for more resources

The study revealed significantly decreased levels of CGRP in COVID-19 patients, with even lower levels in patients treated with proton pump inhibitors. Immunofluorescence showed RAMP1 activity in smooth muscle cells of blood vessels, airway epithelium, and proliferating type II pneumocytes in COVID-19 samples.
Background: To better understand the biology of COVID-19, we have explored the behavior of calcitonin gene-related peptide (CGRP), an angiogenic, vasodilating, and immune modulating peptide, in severe acute respiratory syndrome coronavirus 2 positive patients. Methods: Levels of CGRP in the serum of 57 COVID-19 patients (24 asymptomatic, 23 hospitalized in the general ward, and 10 admitted to the intensive care unit) and healthy donors (n = 24) were measured by enzyme-linked immunosorbent assay (ELISA). In addition, to better understand the physiological consequences of the observed variations, we investigated by immunofluorescence the distribution of receptor activity modifying protein 1 (RAMP1), one of the components of the CGRP receptor, in autopsy lung specimens. Results: CGRP levels were greatly decreased in COVID-19 patients (P < 0.001) when compared to controls, and there were no significant differences due to disease severity, sex, age, or comorbidities. We found that COVID-19 patients treated with proton pump inhibitors had lower levels of CGRP than other patients not taking this treatment (P = 0.001). RAMP1 immunoreactivity was found in smooth muscle cells of large blood vessels and the bronchial tree and in the airways epithelium. In COVID-19 samples, RAMP1 was also found in proliferating type II pneumocytes, a common finding in these patients. Conclusions: The lower levels of CGRP should negatively impact the respiratory physiology of COVID-19 patients due to vasoconstriction, improper angiogenesis, less epithelial repair, and faulty immune response. Therefore, restoring CGRP levels in these patients may represent a novel therapeutic approach for COVID-19.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.0
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available